An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS). The oral compound, also known as TUDCA, is one of the two ingredients in Relyvrio (sodium phenylbutyrate…
News
People who took part in clinical testing of NurOwn, a cell therapy for amyotrophic lateral sclerosis (ALS), and family members have sent a letter in support of Brainstorm Cell Therapeutics and its investigational therapy to the U.S. Food and Drug Administration (FDA). They are also asking for an…
The ALS Association and Paralyzed Veterans of America (PVA) are pressing the Congress to pass legislation boosting the financial support given the spouses and dependents of U.S. veterans whose death comes after nearly a decade of living with amyotrophic lateral sclerosis (ALS) due to their service. Specifically, the…
FundaMental Pharma, a spin-out preclinical neuroscience company from Heidelberg University, in Germany, has just been launched with €10 million in startup seed funding and a goal of developing new treatments for amyotrophic lateral sclerosis (ALS) and other diseases, according to a company…
An international team of researchers discovered how, during development, motor neurons — the nerve cells controlling movement whose death causes amyotrophic lateral sclerosis (ALS) — direct blood vessel growth around them while growing toward target muscles. Specifically, motor neurons were found to secrete a combination of signaling molecules that…
NeuroSense Therapeutics has received the go-ahead to begin enrolling patients in the U.S. and Italy for a Phase 2b clinical trial testing PrimeC, the company’s experimental therapy for amyotrophic lateral sclerosis (ALS). The clinical trial, called PARADIGM (NCT05357950), enrolled its first participant in June. The study is…
A Phase 1/2 clinical trial is investigating the long-term safety and tolerability of BIIB105, Biogen‘s investigational treatment targeting the ataxin-2 protein, in people with amyotrophic lateral sclerosis (ALS). Called ALSpire (NCT04494256), the trial is currently recruiting adults with ALS at 12 sites in the U.S., Canada, and…
ET-101, Eikonoklastes Therapeutics’ experimental gene therapy for amyotrophic lateral sclerosis (ALS), has been designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status is given to investigational therapies with the potential to significantly benefit people with life-threatening or chronically debilitating diseases that affect…
The Lifestyle Healing Institute (LHI), which uses a complementary and alternative medicine approach to care, is touting the success of an amyotrophic lateral sclerosis (ALS) patient whose mobility and quality of life are said to have improved following treatment. The case of Tod, a 60-year-old patient, demonstrates that…
The U.S. Food and Drug Administration (FDA) notified Brainstorm Cell Therapeutics that it will not accept for review a company application asking that its cell-based therapy NurOwn be approved as a treatment for amyotrophic lateral sclerosis (ALS). The FDA decision, in the form of a refusal to file…
Recent Posts
- Swallowing problems affect 1 in 3 hospitalized ALS patients: Study
- Scientists identify blood markers that may predict ALS progression
- ALS caregivers across Canada can now access free professional counseling
- When an ALS caregiver takes a much-needed break from the daily routine
- Advocates push for swift passage of ACT for ALS reauthorization bill